Study S000167

Disposition of [14C]-LY3437943 Following Subcutaneous Administration in Healthy Male Participants

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05757531
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 7
Start: 2023-03-17
Primary completion: 2023-06-23
Lead sponsor: Eli Lilly and Company
Conditions: Healthy
Interventions: DRUG:[¹⁴C]-LY3437943
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J1I-MC-GZBG

Registered primary outcomes

Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [Predose up to 63 days post dose]
Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [Predose up to 63 days post dose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.